Association Between ERCC1 and XPA Expression and Polymorphisms and the Response to Cisplatin in Testicular Germ Cell Tumours

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Jun 29

PMID 23807173

Citations 34

Authors

J Mendoza

J Martinez

C Hernandez

D Perez-Montiel

C Castro

E Fabian-Morales

M Santibanez

R Gonzalez-Barrios

J Diaz-Chavez

M A Andonegui

N Reynoso

L F Onate

M A Jimenez

M Nunez

R Dyer

L A Herrera

Affiliations

Soon will be listed here.

Abstract

Background: Cisplatin cures over 80% of testicular germ cell tumours (TGCTs), and nucleotide-excision repair (NER) modifies the sensitivity to cisplatin. We explored the association between NER proteins and their polymorphisms with cisplatin sensitivity (CPS) and overall survival (OS) of patients with non-seminomatous (ns)-TGCTs.

Methods: The expression of ERCC1 and XPA and the presence of γH2AX were evaluated in cancer cell lines and in fresh ns-TGCTs. The ERCC1 protein was also determined in ns-TGCTs. The differences between CPS and non-CPS cell lines and patients were analysed by Student's t- or χ(2)-tests. The differences in OS were analysed using the log-rank test, and the hazard ratios (HRs) were calculated using the Cox model.

Results: High ERCC1 expression was observed in the non-CPS cells, and both ERCC1 and γH2AX expressions were augmented after cisplatin treatment. Increased ERCC1 expression was also identified in non-CPS patients. Neither polymorphism was associated with either CPS or OS. The presence of ERCC1 was associated with non-CPS (P=0.05) and adjusted in the prognosis groups. The HR in ERCC1-negative and non-CPS patients was >14.43, and in ERCC1-positive and non-CPS patients the HR was >11.86 (P<0.001).

Conclusions: High levels of ERCC1 were associated with non-CPS, suggesting that ERCC1 could be used as a potential indicator of the response to cisplatin and prognosis in ns-TGCTs.

Citing Articles

Crosstalk between DNA Damage Repair and Metabolic Regulation in Hematopoietic Stem Cells.

Xu J, Fei P, Simon D, Morowitz M, Mehta P, Du W Cells. 2024; 13(9.

PMID: 38727270 PMC: 11083014. DOI: 10.3390/cells13090733.

Targeting the DNA Damage Response for Cancer Therapy.

Wang R, Sun Y, Li C, Xue Y, Ba X Int J Mol Sci. 2023; 24(21).

PMID: 37958890 PMC: 10648182. DOI: 10.3390/ijms242115907.

LepR+ niche cell-derived AREG compromises hematopoietic stem cell maintenance under conditions of DNA repair deficiency and aging.

Wu L, Lin Q, Chatla S, Amarachintha S, Wilson A, Atale N Blood. 2023; 142(18):1529-1542.

PMID: 37584437 PMC: 10656728. DOI: 10.1182/blood.2022018212.

XPF-ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer.

Huang M, Huang Y, Cheng T, Jhang W, Ke C, Chen Y Cells. 2023; 12(11).

PMID: 37296596 PMC: 10252687. DOI: 10.3390/cells12111475.

Breaking the Mold: Epigenetics and Genomics Approaches Addressing Novel Treatments and Chemoresponse in TGCT Patients.

Cuevas-Estrada B, Montalvo-Casimiro M, Munguia-Garza P, Rios-Rodriguez J, Gonzalez-Barrios R, Herrera L Int J Mol Sci. 2023; 24(9).

PMID: 37175579 PMC: 10178517. DOI: 10.3390/ijms24097873.

References

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria J . Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell.... Clin Cancer Res. 2007; 13(13):3855-9. DOI: 10.1158/1078-0432.CCR-07-0252. View

Stevens E, Raffeld M, Espina V, Kristensen G, Trope C, Kohn E . Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer. 2005; 103(11):2313-9. DOI: 10.1002/cncr.21031. View

Handra-Luca A, Bilal H, Bertrand J, Fouret P . Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol. 2003; 163(3):957-67. PMC: 1868241. DOI: 10.1016/S0002-9440(10)63455-4. View

Honecker F, Mayer F, Stoop H, Oosterhuis J, Koch S, Bokemeyer C . Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors. Lab Invest. 2003; 83(10):1489-95. DOI: 10.1097/01.lab.0000090221.95883.41. View

Park D, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J . ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol. 2005; 1(3):162-6. View

Leibeling D, Laspe P, Emmert S . Nucleotide excision repair and cancer. J Mol Histol. 2006; 37(5-7):225-38. DOI: 10.1007/s10735-006-9041-x. View

Koberle B, Masters J, Hartley J, Wood R . Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol. 1999; 9(5):273-6. DOI: 10.1016/s0960-9822(99)80118-3. View

Yu J, Mu C, Lee K, Okamoto A, Reed E, Mitchell K . A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res. 1997; 382(1-2):13-20. DOI: 10.1016/s1383-5726(97)00004-6. View

10.

Koberle B, Roginskaya V, Zima K, Masters J, Wood R . Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation. Mol Carcinog. 2008; 47(8):580-6. DOI: 10.1002/mc.20418. View

11.

Koberle B, Grimaldi K, Sunters A, Hartley J, Kelland L, Masters J . DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer. 1997; 70(5):551-5. DOI: 10.1002/(sici)1097-0215(19970304)70:5<551::aid-ijc10>3.0.co;2-g. View

12.

Al-Haddad S, Zhang Z, Leygue E, Snell L, Huang A, Niu Y . Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol. 1999; 155(6):2057-66. PMC: 1866920. DOI: 10.1016/S0002-9440(10)65524-1. View

13.

Usanova S, Piee-Staffa A, Sied U, Thomale J, Schneider A, Kaina B . Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer. 2010; 9:248. PMC: 3098011. DOI: 10.1186/1476-4598-9-248. View

14.

Steffensen K, Waldstrom M, Jeppesen U, Brandslund I, Jakobsen A . Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer. 2007; 18(4):702-10. DOI: 10.1111/j.1525-1438.2007.01068.x. View

15.

Jones R, Vasey P . Part II: testicular cancer--management of advanced disease. Lancet Oncol. 2003; 4(12):738-47. DOI: 10.1016/s1470-2045(03)01279-8. View

16.

Koberle B, Brenner W, Albers A, Usanova S, Thuroff J, Kaina B . ERCC1 and XPF expression in human testicular germ cell tumors. Oncol Rep. 2009; 23(1):223-7. View

17.

Saldivar J, Lu K, Liang D, Gu J, Huang M, Vlastos A . Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol. 2007; 107(1 Suppl 1):S223-9. DOI: 10.1016/j.ygyno.2007.07.024. View

18.

Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg D, Wain J . Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004; 10(15):4939-43. DOI: 10.1158/1078-0432.CCR-04-0247. View

19.

Park J, Jeon E, Chun S, Won H, Lee A, Hur S . ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer. Gynecol Oncol. 2010; 120(2):275-9. DOI: 10.1016/j.ygyno.2010.10.034. View

20.

Koberle B, Payne J, Grimaldi K, Hartley J, Masters J . DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol. 1996; 52(11):1729-34. DOI: 10.1016/s0006-2952(96)00549-7. View